🐻 PRAX $3.1M LEAP Put — Disaster Insurance After a 520% Rocket Ride

📅 April 24, 2026 | 🔥 Unusual Activity Detected

---

🎯 The Quick Take

Someone just dropped $3.1 MILLION on deep out-of-the-money LEAP puts on PRAX — a clinical-stage neuro biotech that has already rocketed +520% in six months after its Essential3 Phase 3 win. The trade: a $220 strike put expiring February 19, 2027, struck 35% below the current $337.74 spot price, paying $31 per contract for 1,000 contracts with zero existing open interest. Translation: this is brand-new, purpose-built disaster insurance — and someone paid $3.1M to own it.

---

📊 Company Overview

Praxis Precision Medicines (NASDAQ: PRAX) is a clinical-stage CNS biopharmaceutical company developing precision medicines for epilepsy and essential tremor:

• Market Cap: ~$9.3B (27.85M shares outstanding as of April 11, 2026) — per stockanalysis.com
• Industry: Biotechnology / Clinical-Stage CNS Neuroscience
• Current Price: ~$337.74 (52-week range spans sub-$30 pre-October 2025 to highs above $360 in April 2026) — per Yahoo Finance PRAX
• Cash Runway: ~$1.5B pro-forma after January 2026 raise, funding operations into 2028 — per Praxis Q4 2025 press release
• Revenue: Zero — pre-commercial, earliest launch Q4 2026 / Q1 2027

What they do: Praxis is targeting two massive CNS markets simultaneously. Their lead drug ulixacaltamide (NDA accepted, PDUFA January 29, 2027) would be the first novel essential tremor therapy approved in decades — addressing a condition affecting an estimated 10M+ Americans currently relying on off-label propranolol. Their second drug relutrigine (PDUFA September 27, 2026) is on priority review as a potential first-in-class treatment for SCN2A- and SCN8A-related developmental epileptic encephalopathies. Then there's vormatrigine (POWER1 Phase 2/3 readout due 1H 2026) targeting focal onset seizures.

This is an extraordinary pipeline density for a company that was trading below $60 just six months ago.

---

💰 The Option Flow Breakdown

📊 The Tape — April 24, 2026

🤓 What This Actually Means

Let's break down what just happened — because this trade is fascinating once you understand the structure:

• 💸 $3.1M paid upfront: 1,000 contracts × 100 shares × $31 = exactly $3.1M all-in. This is not a spread — they're holding raw downside exposure.
• 🎯 35% out-of-the-money: PRAX would need to fall from $337.74 to BELOW $220 for this trade to make money at expiration. That's not a normal hedge. That's tail-risk insurance.
• 📅 10-month time horizon: February 19, 2027 expiration means this trade spans both PDUFA dates — relutrigine (September 27, 2026) AND ulixacaltamide (January 29, 2027). Whoever bought this is explicitly positioning for something to go wrong across that entire window.
• 🚨 Zero open interest: This trade created its own open interest from scratch. Nobody was selling these $220 puts before this moment. This is a new, deliberate position — not a roll, not a close.
• 🏦 $31 per contract is not cheap: On a $337 stock, that's 9.2% of the stock price paid in premium for an option that's 35% out-of-the-money. Implied volatility on biotech LEAPs is high, but this buyer accepted that cost without blinking.

Real talk: When a clinical-stage biotech with zero revenue has rallied 520% in six months and is sitting at a $9.3B market cap, the bull thesis is almost entirely dependent on a sequence of binary events going right. This $3.1M put buyer is making exactly that bet — not that PRAX crashes tomorrow, but that somewhere in the next ten months, something breaks, and when it does, the stock doesn't stop at $300 or $280. It goes much lower.

This is the institutional equivalent of buying fire insurance on a house that just tripled in price. You hope you never need it.

---

📈 Technical Setup / Chart Check-Up

YTD Performance Chart

PRAX has one of the most dramatic YTD charts in biotech. Per Zacks coverage of the rally, the stock launched from sub-$60 levels following the October 16, 2025 Essential3 Phase 3 success and has never looked back — printing multi-year highs above $360 in April 2026.

Key observations from the chart:

• 🚀 Parabolic structure: The move from sub-$60 to $337+ is nearly vertical, the classic biotech-catalyst moonshot pattern
• 🏔️ Consolidation zone: Stock has been grinding between roughly $300–$365 for several weeks, digesting the post-NDA-acceptance rally
• ⚠️ Extended at current levels: At ~$9.3B market cap for a pre-revenue company, the stock is pricing in substantial success across multiple binary events
• 📊 Volume support: Heavy accumulation post-Essential3 with institutional rotation around BTIG's upgrade to $843 and Piper Sandler's $1,200 price target — per MarketBeat analyst ratings

Gamma-Based Support & Resistance Analysis

GEX Current Price Reference: ~$344.82

The gamma exposure map paints a clear picture of near-term price gravity and the barriers that matter:

🔵 Support Levels (Put Gamma Below Price):

• $340 — Immediate floor, strongest nearby support (total GEX 0.099). Only 1.4% below current price — this is the first line of defense
• $330 — Secondary support (total GEX 0.008), roughly 4.3% below
• $320 — Meaningful put wall (total GEX 0.067), 7.2% lower — put gamma dominates here with net GEX turning bearish, meaning dealers have hedging pressure
• $310 — Another put-heavy level (total GEX 0.060), 10.1% below — dealers short gamma here, which can amplify moves downward
• $300 — Round-number psychological floor (total GEX 0.025); net call GEX positive suggests slight dealer buying support
• $290 — Extended support zone (total GEX 0.032), 15.9% down
• $280 — Deep floor (total GEX 0.018), 18.8% below current price

🟠 Resistance Levels (Call Gamma Above Price):

• $350 — Immediate ceiling, only 1.5% above; mixed call/put GEX makes this a choppy zone rather than a hard wall
• $400 — Major upside barrier (total GEX 0.009), 16% above — strong net call GEX means dealers sell into rallies here
• $410 — Extended resistance (total GEX 0.011), 18.9% above; pure call gamma with no put offset — dealers are short gamma and will sell aggressively

Net GEX Bias: BEARISH — Total put GEX (0.284) exceeds total call GEX (0.202), meaning the aggregate positioning of options market makers creates a downward drag bias. This is not common and tends to amplify both down-moves and volatility.

What this means for traders: PRAX is currently pinned between $340 support and $350 resistance — a tight 3% band. The bearish net GEX bias means any meaningful catalyst (POWER1 miss, clinical setback, macro selloff) could accelerate a breakdown rather than finding a floor. The $320 and $310 levels show concentrated put gamma that would accelerate selling if price reaches those zones.

Implied Move Analysis

Options market pricing for upcoming expirations:

• 📅 Monthly OPEX (May 15 — 21 days out): ±$44.62 (±12.9%) → Range: $300.19 – $389.44

Translation for regular folks: The options market is pricing in a nearly $45 move in either direction just through mid-May. On a $337 stock, that's the equivalent of the market saying: "We have no idea where this thing is going, and we're charging accordingly." The lower end of that range — $300 — sits right at a meaningful gamma support level.

Here's the key insight: If PRAX can't hold $300 on a moderate selloff, the next meaningful gamma support doesn't appear until $290 and $280. And if the broader market turns volatile or a clinical readout disappoints, $280 to $220 — where the put buyer struck — suddenly doesn't look insane anymore.

The $3.1M put buyer is not betting on tomorrow's move. They're betting on the cumulative probability that PRAX, over 10 months of binary events, eventually revisits a price 35% lower. Given the bearish net GEX setup and the density of upcoming catalysts, that's not a crazy bet — it's a sophisticated one.

---

🎪 Catalysts

🔥 Immediate Catalysts (Next 30 Days)

Q1 2026 Earnings — Expected May 1, 2026 (Before Market Open)

Per MarketBeat earnings calendar, PRAX reports Q1 results in roughly one week. With zero revenue, the market will focus on:

• 💰 Cash burn rate (Q4 2025 OpEx was $97M; what's the Q1 2026 run-rate?)
• 📣 Reiteration of POWER1 timing — any push from "1H 2026" to "2H 2026" would hit the stock hard
• 🏥 SG&A ramp progress (field force hiring signals ET launch confidence)
• 🎯 Ulixacaltamide pricing strategy commentary — any pullback from $36K net price narrative changes models materially

AAN Annual Meeting 2026 (April 2026 — Recently Completed)

Detailed Essential3 data presented — the mADL11 improvement was rated "clinically meaningful" by attending neurologists, and the stock reacted favorably. This is now a tailwind baked in.

🚀 Near-Term Catalysts (1H 2026 — THE BIG ONE)

POWER1 Topline Readout — Vormatrigine (Focal Onset Seizures): Expected 1H 2026

This is the most important near-term binary for PRAX. The Phase 2/3 POWER1 trial for vormatrigine in focal onset seizures has completed enrollment, with topline results expected in 1H 2026. Phase 2 RADIANT data showed 56.3% median decrease in seizure frequency over 8 weeks — a strong signal.

However, the Street prices this at only ~60-70% probability of success. A POWER1 miss would erase an estimated $400M+ of vormatrigine value embedded in consensus models and could move the stock -25% to -40% in a single session. That is the disaster scenario the $3.1M put buyer is explicitly insuring against — a $337 stock dropping to $200-$250 on a Phase 3 failure.

Relutrigine PDUFA — September 27, 2026 (Priority Review)

Per Praxis IR release and BioSpace coverage, the FDA accepted the relutrigine NDA under priority review for SCN2A- and SCN8A-DEEs — rare pediatric epilepsies. This drug holds Orphan Drug, Rare Pediatric Disease, and Breakthrough Therapy designations. Analyst consensus pegs approval probability at ~75-85% given the strong Phase 2 EMBOLD open-label extension data showing ~90% mean seizure reduction at 11 months. A Rare Pediatric Disease Priority Review Voucher could be worth ~$100M if granted.

Ulixacaltamide PDUFA — January 29, 2027 (THE BLOCKBUSTER)

Per GlobeNewswire announcement, the FDA accepted the ulixacaltamide NDA with a PDUFA date of January 29, 2027 — just ten days before the February 19, 2027 expiration of this $3.1M put. The drug holds FDA Breakthrough Therapy Designation granted December 2025.

If approved, analysts model peak sales from $5B (Guggenheim) to $6B (Piper Sandler base case) — Guggenheim's analysis cites a >$15B total ET market opportunity. BTIG recently raised its assumed net U.S. price to $36,000/year from $14,000. This is the bet the bulls are running — a first-in-class ET drug with no modern approved competition.

The bear risk: a narrow label (severe-only restriction instead of broad ET) or a Complete Response Letter would be catastrophic for the thesis.

✅ Recent Catalysts (Already Happened — Positive)

January 2026 Capital Raise (~$621M)

Praxis raised ~$621M via a public offering, extending the pro-forma cash balance to ~$1.5B and confirming runway into 2028 — well past every binary event above.

Q4 2025 Results (February 19, 2026)

Per Motley Fool Q4 2025 transcript, cash at year-end 2025 was $926M, full-year net loss was $303.3M. Management confirmed 2028 runway. No surprises.

Ulixacaltamide FDA Breakthrough Therapy Designation (December 2025)

Per Praxis IR release, FDA granted Breakthrough Therapy Designation for ulixacaltamide for essential tremor — a meaningful regulatory accelerant.

China Licensing Deal (Ongoing)

Ulixacaltamide Greater China rights licensed to Tenacia Biotechnology per Praxis IR Tenacia release, with up to $264M in milestones plus tiered royalties. Total deal value exceeds $275M.

---

🎲 Price Targets & Probabilities

Using gamma levels and implied move data through the May 15 OPEX, combined with the forward catalyst window:

📈 Bull Case (30% probability through Feb 2027 LEAP expiry)

Target: $400–$450+

How we get there:

• 💊 POWER1 vormatrigine SUCCEEDS (most critical catalyst in 1H 2026) — validates the third program, adds $400M+ to consensus valuation
• ✅ Relutrigine approved September 27, 2026 (75-85% analyst probability per TipRanks consensus) — PRV voucher bonus of ~$100M
• 🏥 Ulixacaltamide NDA approval January 29, 2027 with broad ET label — stock re-rates toward Piper Sandler $1,200 or BTIG $843 targets
• 📈 Gamma resistance at $350, $400, $410 gets absorbed by institutional buying as successes stack up
• 💰 Ex-U.S. licensing announcements for EU/Japan ulixacaltamide add milestone upside

What this means for the $3.1M put: Expires essentially worthless. The put buyer lost their $31/contract ($3.1M total) — which they were likely willing to accept as insurance cost on a much larger long position.

🎯 Base Case (40% probability)

Target: $280–$360 (Volatile Consolidation with Mixed Catalysts)

Most likely scenario:

• ⚖️ POWER1 result is mixed or delayed — vormatrigine data comes in 2H instead of 1H, pushing the catalyst into the option's window
• ✅ Relutrigine approved on schedule but with narrow label — revenue ramp slower than modeled
• 📊 Ulixacaltamide PDUFA approaches with uncertainty — AdCom announced creates near-term volatility
• 🔄 Stock oscillates within the $300–$360 gamma band as catalysts trickle in
• 💸 The implied move of ±12.9% (±$44.62) through May 15 alone tells you to expect $45 swings per month — multiply that by 10 months and you see why a $220 put could become relevant

What this means for the $3.1M put: Depending on path, the put carries some value into the $260–$280 zone (if POWER1 disappoints or label is narrow) or decays slowly if everything stays on track. Not a home run, but not a total loss.

📉 Bear Case (30% probability — THE PUT BUYER'S SCENARIO)

Target: $150–$220 (Test or Breach the Strike)

What could go wrong:

• 💊 POWER1 MISSES — focal onset seizures is a large commercial opportunity; failure removes ~$400M from models and triggers institutional de-risking. Stock drops 25–40% in one session. From $337, that's $200–$250 range instantly
• ❌ POWER1 miss triggers contagion doubt about vormatrigine mechanism — investors start discounting the relutrigine story too
• 📉 Relutrigine CRL (small Phase 2 sample base — FDA could request larger safety data) sends stock another leg lower
• 💸 Commercial launch risk for ET — payer step-therapy gates, prior authorization hurdles, net pricing below $36K assumption
• 📊 Macro biotech selloff (rate shock, IRA drug pricing expansion) compresses the multiple on a pre-revenue $9.3B company
• 🏢 Insider selling continues — per InsiderTrades data, 16 open-market sales vs. 0 purchases in trailing 6 months for General Counsel Alex Nemiroff (~$4.85M in sales alone)

Put P&L in Bear Case:

• 📉 PRAX at $250 by February 19, 2027: Put worth ~$0 (still out-of-the-money). Need to go below $220.
• 💔 PRAX at $220 on expiry: Put worth ~$0 (at-the-money). Break-even point.
• 💰 PRAX at $180 on expiry: Put worth $40 → profit = $9 per contract × 1,000 = $900K gain (29% ROI)
• 🚀 PRAX at $120 on expiry: Put worth $100 → profit = $69 per contract × 1,000 = $6.9M gain (222% ROI)

The key insight: This put doesn't make money unless PRAX falls more than 35% from today's levels. That requires a genuine disaster — a Phase 3 failure, a CRL on a key drug, or a combination of negative catalysts. The buyer isn't betting on a correction; they're betting on a catastrophe.

---

💡 Trading Ideas

🛡️ Conservative: Watch the POWER1 Catalyst Window, Then Decide

The "Show Me the Data" Strategy

POWER1 vormatrigine topline data is the single most important catalyst in the near term. Before that data is in, PRAX is essentially a binary option on clinical success — and the implied volatility priced into near-term options reflects that.

Why this works:

• ⏰ Options are expensive right now (biotech binary pricing); after POWER1 clears, IV resets
• 🎯 If POWER1 succeeds, buy PRAX stock on any pullback to $300 gamma support — excellent entry for the relutrigine and ulixacaltamide PDUFA runway
• ❌ If POWER1 misses, the stock re-prices lower and the real opportunity emerges — either short-dated puts on the bounce or stock accumulation at $200-$250 levels
• 📊 Cash position now, decision after the readout — you preserve all optionality

Action plan:

• 👀 Watch for POWER1 announcement (expected 1H 2026 — could literally be any week)
• 🎯 Set alerts for PRAX news; a Phase 3 miss will be the headline on every biotech site within minutes
• ✅ After POWER1 clears, reassess gamma levels and re-enter with defined risk

Risk level: Minimal (observation only) | Skill level: All levels

⚖️ Balanced: Put Spread to Define Risk on Downside

The "Copy the Hedge but Cheaper" Strategy

Instead of spending $3.1M on raw puts, retail traders can construct a defined-risk put spread that profits if PRAX breaks down, while capping cost.

Structure (illustrative): Buy the $280 put / Sell the $250 put, targeting a November or January expiration

Why this works:

• 💰 Cost: a $30-wide put spread runs roughly $6-10 (vs. $31 for the outright put) — dramatically cheaper
• 🎯 Profit zone: $250 and below, with max profit around $20-24 per spread if PRAX crashes
• 🛡️ Defined max loss: only the premium paid (no additional risk)
• ⏰ Captures the POWER1 readout AND the relutrigine PDUFA in a single position
• 📊 Breakeven around $270-274 — requires only a 20% correction vs. the 35% the outright put needs

Things to watch:

• 🔍 Enter only after POWER1 is resolved OR if the stock breaks below $300 gamma support (confirming downside momentum)
• ⚠️ Biotech options are expensive — check bid-ask spreads before entering (wide spreads in low-liquidity names eat returns)
• 💸 Size conservatively: 1-5% of portfolio maximum on a speculative directional biotech play

Risk level: Moderate (defined risk) | Skill level: Intermediate

🚀 Aggressive: Short-Dated Puts Around POWER1 Binary

The "Catalyst Sniper" Strategy (Advanced Only)

If you have a high-conviction view that POWER1 will MISS, short-dated puts immediately before the data readout can deliver explosive returns — but this is pure binary speculation.

Structure (illustrative): Buy near-the-money $300 or $320 puts expiring the month AFTER the expected POWER1 readout

Why this could work:

• 💥 A Phase 3 miss from $337 could drop the stock 25-40% in one session — from $337 to $200-$250
• 📊 Near-the-money puts would go from $10-15 to $50-80+ overnight on a miss (3-5x return)
• ⏰ Short-dated contracts maximize gamma exposure for rapid price moves
• 🎯 POWER1 is the single event with the highest magnitude impact in the near-term window

Why this could blow up (SERIOUS RISKS):

• 😱 If POWER1 succeeds, the stock gaps UP 25-40% and your puts expire worthless immediately
• 💸 IV crush on a positive readout — options lose value on both legs as volatility collapses post-data
• ⏰ Timing risk — if POWER1 data comes later than expected (pushed to 2H), short-dated puts decay badly
• 🎢 PRAX has shown it can move 15-20% in either direction on a single catalyst

CRITICAL WARNING: This is a coin-flip binary trade. Only attempt if you can afford to lose 100% of premium, understand biotech catalyst mechanics, and have a specific data-based thesis for why POWER1 will miss. Position size should be 1-3% of portfolio maximum.

Risk level: EXTREME | Skill level: Advanced only

---

⚠️ Risk Factors

The landmines that matter:

• 💊 POWER1 binary is the elephant in the room: The vormatrigine Phase 2/3 readout expected in 1H 2026 is a coin-flip (60-70% bull probability by Street estimates). A miss doesn't just remove $400M from models — it raises questions about the entire NaV platform's translatability, potentially casting doubt on the other programs. This is the single highest-magnitude risk in the near term.

• 💰 Valuation bakes in near-perfect execution: At ~$9.3B market cap for a company with zero revenue, PRAX is pricing in successful launches of ulixacaltamide AND relutrigine AND vormatrigine at peak-case pricing. Piper Sandler's $1,200 PT per MarketBeat is the upside case — and the street-low from Wedbush is $83. That $83-to-$1,200 range tells you everything about how uncertain the outcome truly is.

• 🏢 Insider selling is a yellow flag: Per InsiderTrades.com data, there have been 16 open-market insider sales vs. 0 purchases in the trailing six months. General Counsel Alex Nemiroff alone sold 25,130 shares (~$4.85M). CEO Marcio Souza has not transacted — a mild positive — but the overall pattern of executives selling into the rally warrants attention.

• 🏥 Commercial launch risk for a first-in-class drug: Essential tremor is largely treated with cheap generics (off-label propranolol). Getting payers to cover a $36K/year drug with prior authorization requirements for 10M+ patients with varying severity is a multi-year commercial challenge. Even with FDA approval, commercial execution risk is real — and the Wedbush $83 bear case is essentially a commercial disappointment scenario.

• ⚖️ Label breadth is critical for ulixacaltamide: A narrow FDA label (severe ET only vs. broad ET) materially changes the addressable population and peak sales curve. The difference between a "full ET" label and a "severe, refractory ET" label could be worth $3-5B in peak sales — and that's not knowable until the PDUFA decision.

• 🌎 Biotech sector macro headwinds: PRAX is a high-beta, pre-revenue biotech trading at a $9.3B premium. In a risk-off environment (rate shock, IRA drug pricing expansion, broader biotech selloff), it would be among the first names to reprice lower — regardless of clinical fundamentals. The implied move of ±12.9% through just May 15 OPEX shows the market is already nervous.

• 🔬 Small data sets underlying two of three NDAs: Relutrigine's NDA is based on a Phase 2 open-label extension; the FDA could request a larger safety database before approval. Per the catalysts research, an Advisory Committee meeting has not yet been announced for relutrigine — that announcement could itself be a volatility event.

• 📉 35% OTM is a big ask: The $220 put is 35% below spot. For retail traders watching this trade for signals: the fact that someone paid $3.1M for a 35% OTM LEAP is NOT a prediction of where the stock goes. It's protection against a catastrophic scenario. Most LEAPs this deep out-of-the-money expire worthless. That's the point — insurance usually doesn't pay off.

---

🎯 The Bottom Line

Real talk: Someone just dropped $3.1M to own a put on one of the hottest biotech names in the market — and they did it 35% out-of-the-money, with 10 months on the clock, and zero open interest to open the position. This is not a panic trade. This is a calculated, sophisticated piece of disaster insurance.

What this trade is NOT saying:

• ❌ It is not saying PRAX crashes to $220 tomorrow
• ❌ It is not saying the science is broken or the drugs won't work
• ❌ It is not a signal to sell PRAX or go short

What this trade IS saying:

• 🎯 Someone with serious money believes the downside scenario — specifically a 35%+ collapse from here — has meaningful probability over the next 10 months
• 🗓️ They specifically structured to span BOTH PDUFA dates (relutrigine September 27, 2026 and ulixacaltamide January 29, 2027) — plus POWER1 vormatrigine readout
• 💡 They accepted paying $31/contract (9.2% of spot price) for a strike 35% out-of-the-money — that's a LOT of insurance premium, which means the risk they're protecting against is real to them
• 🐻 The net GEX bias is already bearish on PRAX — market makers are net short gamma, which amplifies volatility in both directions

Mark your calendar — the key dates:

• 📅 ~May 1, 2026 — Q1 2026 earnings; watch for POWER1 timing guidance
• 📅 1H 2026 (any week) — POWER1 vormatrigine topline readout (biggest near-term binary)
• 📅 September 27, 2026 — Relutrigine PDUFA (priority review; ~75-85% approval probability)
• 📅 January 29, 2027 — Ulixacaltamide PDUFA (the blockbuster decision; 10 days before this put expires)
• 📅 February 19, 2027 — This $3.1M put expires

Three scenarios for existing PRAX holders:

🟢 Own it and holding: Consider taking some chips off the table into the POWER1 binary. Up 520% is an extraordinary gain — locking in even 30% of the position protects against the catastrophic downside that the LEAP put buyer is insuring against. You can always re-enter lower.

🟡 Watching from sidelines: Do NOT chase here at $337 ahead of POWER1. Wait for the binary to clear. If POWER1 succeeds, buy the dip on any pullback to $300-$320 for the PDUFA runway. If POWER1 fails, the real opportunity emerges at $200-$250 levels.

🔴 Bearish: The $3.1M LEAP put is a sophisticated template but extremely expensive for retail traders. The defined-risk alternative — a put spread — offers similar directional exposure at a fraction of the premium. Wait for POWER1 resolution before taking any bearish positioning; fighting the momentum of a 520% rally before a binary catalyst is not a strategy — it's a gamble.

The lesson here: Biotech LEAPs after monster rallies are where the smart money quietly buys insurance while the retail crowd chases momentum. This $3.1M trade is a reminder that even in the most exciting biotech stories — two PDUFAs, Breakthrough designations, a $1.5B war chest — the path from here to commercialization runs directly through a series of coin flips. Respect the binary risk. Manage your size. And if you're holding a 5x winner, there's no shame in protecting some of it.

Disclaimer: Options trading involves substantial risk of loss and is not suitable for all investors. This analysis is for educational purposes only and does not constitute investment advice or a recommendation to buy or sell any security. Past option flow activity does not predict future stock performance. Clinical-stage biotech stocks carry extreme binary event risk, including the possibility of losing the entire investment. The $3.1M put trade analyzed here may reflect hedging of a larger position, portfolio insurance, or institutional risk management strategies that may not be appropriate or applicable for retail traders. The $220 strike is 35% below current price and has a low probability of being in-the-money at expiration. Always conduct your own due diligence and consult a licensed financial advisor before making investment decisions.